| Literature DB >> 32400365 |
Nupur Kittur1, Carl H Campbell1, Sue Binder1, Ye Shen2, Ryan E Wiegand3,4,5, Joseph R Mwanga6, Safari M Kinung'hi7, Rosemary M Musuva8, Maurice R Odiere8, Sultani H Matendechero9, Stefanie Knopp4,5, Daniel G Colley1,10.
Abstract
The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) conducted large field studies on schistosomiasis control and elimination in Africa. All of these studies, carried out in low-, moderate-, and high-prevalence areas, resulted in a reduction in prevalence and intensity of Schistosoma infection after repeated mass drug administration (MDA). However, in all studies, there were locations that experienced minimal or no decline or even increased in prevalence and/or intensity. These areas are termed persistent hotspots (PHS). In SCORE studies in medium- to high-prevalence areas, at least 30% of study villages were PHS. There was no consistent relationship between PHS and the type or frequency of intervention, adequacy of reported MDA coverage, and prevalence or intensity of infection at baseline. In a series of small studies, factors that differed between PHS and villages that responded to repeated MDA as expected included sources of water for personal use, sanitation, and hygiene. SCORE studies comparing PHS with villages that responded to MDA suggest the potential for PHS to be identified after a few years of MDA. However, additional studies in different social-ecological settings are needed to develop generalizable approaches that program managers can use to identify and address PHS. This is essential if goals for schistosomiasis control and elimination are to be achieved.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32400365 PMCID: PMC7351310 DOI: 10.4269/ajtmh.19-0815
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 2.345
Figure 1.Line graphs showing prevalence at baseline (Y1) and final survey (Y5) in individual villages in study arms that received 4 years of annual school-based treatment in the SCORE Kenya and Tanzania gaining control studies. Gray lines depict villages that showed ≥ 35% reduction in prevalence, whereas black lines depict villages with < 35% reduction in prevalence from baseline to year 5. This figure is a composite of data presented in Ref. 2.
Figure 2.Donut graph depicting the proportion of persistent hotspots in SCORE gaining and sustaining control studies in Year 5 in study arms that had mass drug administration (MDA) twice in 4 years (inner ring) compared with study arms that had MDA every year (outer ring). χ2 P-value is indicated for each comparison. * Indicates statistical significance at P < 0.05. The data in this figure are re-graphed from data presented in Ref. 2.
Definitions of PHS in SCORE field studies
| SCORE study | Definition of PHS |
|---|---|
| Sustaining and gaining control studies | Villages that failed to achieve at least a 35% decrease in prevalence relative to baseline and/or a 50% decrease in infection intensity relative to baseline after 4 years of mass drug administration, either annually or twice in 4 years |
| Kenya and Tanzania factors study | Villages with a starting prevalence of ≥ 50% that remained at ≥ 25% prevalence at the end of the study while responders reduced to a < 25% prevalence, or those with a starting prevalence of 25–49% that remained at ≥ 10% prevalence at the end of the study while responders reduced to < 10% prevalence |
| Zanzibar elimination study | Shehias with a prevalence ≥ 10% at baseline and ≥ 5% at the end of the study |
PHS = persistent hotspots; SCORE = Schistosomiasis Consortium for Operational Research and Evaluation.